Overview: Parainfluenza IgM TestIntroduction: The Parainfluenza IgM Test tests for parainfluenza IgM antibodies to diagnose recent respiratory infections, helping manage symptoms like cough or fever. Affecting 1 in 1,000 children annually, parainfluenza poses diagnostic challenges due to acute onset. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses ELISA for high accuracy, supporting virology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in pediatrics.
Other Names: Parainfluenza IgM Antibody Test, Recent Infection Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: Parainfluenza IgM testing began in the 1980s with research by Welliver, who identified antibody response. ELISA advancements in the 1990s by Thermo Fisher improved detection, surpassing earlier immunofluorescence methods.
Purpose: Detects parainfluenza IgM levels to diagnose recent infections, guides supportive care, and evaluates patients with respiratory symptoms, aiming to manage disease.
Test Parameters: Parainfluenza IgM levels
Pretest Condition: No special preparation required. Collect serum. Report history of respiratory issues.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document recent respiratory symptoms. Include current medications or exposure history.
Consent: Written consent required, detailing the test's purpose, infection risks, and sample collection risks.
Procedural Considerations: Uses ELISA to measure IgM, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive IgM suggests recent infection, guiding care. Early treatment might prevent complications, while untreated cases lead to worsening. Negative results may require other tests.
Specialist Consultation: Consult a pediatrician or infectious disease specialist for interpretation.
Additional Supporting Tests: RT-PCR, chest X-ray, or viral culture to confirm diagnosis.
Test Limitations: Specific to IgM; correlation with symptoms needed. False negatives possible in early infection.
References: CDC Guidelines, 2023; Pediatric Infectious Disease Journal, Welliver RC, 2022.
